New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical’s BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure
– Bioreactance-based Noninvasive Measurements During Exertion Identified
Abnormalities of Cardiovascular Function and Might be Useful for Indexing
Disease Severity, Prognostication, and for Tracking Responses to Treatment in
Clinical Practice and Trials
Results from a multicenter study of Cheetah Medical’s Exercise Cardiac
Output (ECO(R)) stress test protocol for chronic heart failure were published
earlier this month in the Journal of Cardiac Failure, the official journal of
the Heart Failure Society of America and the Japanese Heart Failure Society.
With approximately 6 million Americans diagnosed with heart failure, it is a
leading cause of morbidity and mortality. After heart failure is diagnosed,
the 1-year mortality rate is high, with 1in 5 dying. Eighty percent of men
and 70% of women 65 years of age who have heart failure will die within 8
years, and one in 8 US deaths has HF mentioned on the death certificate.
Unfortunately, heart failure specialists have limited tools with which to
monitor heart failure progression, determine prognosis and response to
treatment. Recently, it was shown that peak Cardiac Output and Peak Cardiac
Power Output are the strongest predictors of heart failure severity, however
access to these current methods is limited to a minute portion of heart
failure patients due to cost and complexity of the devices.
In this study, Cheetah Medical’s NICOM(R) System was used to continuously
monitor the Cardiac Output response during exercise stress testing as well as
Cardiac Power Output and a host of other hemodynamic parameters in patients
with varying degrees of chronic heart failure and compared to the traditional
method of measuring oxygen consumption which are obtained from analysis of
expired gases. The results from both methods correlated extremely well,
demonstrating the potential to use the NICOM system to routinely monitor
heart failure patients without the significant limitations of expired breath
gas technologies.
Laboratory for the Elderly, Associate Professor of Clinical Medicine at
said: “We continually search for practical means of assessing the status of
our heart failure patients that are useful both for routine clinical practice
and for clinical research. Although the usefulness of measuring oxygen
consumption is well established, these data suggest that additional
physiologic and prognostic information can be obtained using the NICOM, which
is as easy to measure as an electrocardiogram and does not require special
training for its interpretation.”
Adjunct Associate Professor of Medicine at
and a leading clinical researcher in the field of heart failure added, “With
the results of this study showing good correlations to oxygen consumption and
several prior independent studies showing that peak cardiac power can be even
more predictive of outcomes, we are encouraged that we will see these
measurements used more often in a variety of settings. Currently, the NICOM
appears to offer the simplest solution for clinicians to measure cardiac
output and power during exercise. We are planning a large multicenter study
to confirm the prior smaller studies to prove the utility of peak cardiac
power for predicting the risks of hospitalizations, the need for heart
transplant, left ventricular assist devices and mortality.”
About Cheetah Medical
Cheetah Medical delivers accurate noninvasive cardiac output (CO),
noninvasive blood pressure (NIBP), stroke volume variation (SVV), total
peripheral resistance (TPR) and other vital hemodynamic monitoring parameters
to provide continuous, clinically actionable information for fluid and drug
optimization in acute and ambulatory care settings, including intensive care,
emergency, perioperative care, dialysis and outpatient cardiology. The
NICOM(R) Noninvasive Cardiac Output & Hemodynamic Monitoring System uses
Cheetah Medical’s proprietary BIOREACTANCE(R) Technology, which has validated
performance accuracy and faster directional changes compared to invasive CO
measurement methods, with less potential costs and risks. Cheetah Medical
worldwide headquarters are located in
headquarters are located in
website at http://www.cheetah-medical.com.
For More Information Contact:
Yoav Avidor, MD
Chief Executive Officer
Cheetah Medical
yoav@cheetah-medical.com
Telephone: +972-3-644-0288
SOURCE Cheetah Medical Ltd